Prevalence of polypharmacy and associated factors among patients living with HIV infection in Spain: The POINT study
| Autor: | Mercedes Gimeno-Gracia, Carmen V Almeida-González, Ramón Morillo-Verdugo, María de Las Aguas Robustillo-Cortés, Javier Sánchez-Rubio-Ferrández |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty 030106 microbiology Population Human immunodeficiency virus (HIV) Pharmacy HIV Infections medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Internal medicine Antiretroviral treatment Prevalence Medicine Multimorbidity Humans 030212 general & internal medicine education Polypharmacy education.field_of_study business.industry Medication regimen Cross-Sectional Studies Spain business Viral load |
| Zdroj: | Enfermedades infecciosas y microbiologia clinica (English ed.). 40(1) |
| ISSN: | 2529-993X |
| Popis: | Purpose Survival in people living with HIV (PLWH) has increased and thus people are aging with HIV, increasing the frequency of multimorbidity and polypharmacy. This cross-sectional study was conducted to evaluate the prevalence of polypharmacy among PLWH who were on antiretroviral treatment and were followed in an outpatient setting by the pharmacy department of several hospitals across Spain. In addition, we aimed to evaluate factors associated with polypharmacy and treatment complexity among this population. Material and methods We recorded information on demographic data, data on disease control including viral load and CD4 count at the time of inclusion, comorbidities, pharmacologic treatment and drugs interactions. Polypharmacy was defined as the use of 6 or more different drugs, including antiretroviral medication; major polypharmacy was defined as the use of ≥11 different drugs. Results Overall, 1225 PLWH were eligible in the study. The median (IQR) age was 49 (40–54). Comorbidities were present in 819 (67%) PLWH and 571 (47%) had two or more comorbidities. Overall, 397 (32.4%, 95% CI 29.8–34.9) PLWH met the criteria for polypharmacy, and 67 (5.5%, 95% CI, 4.2–6.7) had major polypharmacy. Several factors were associated with polypharmacy such as type of antiretroviral treatment, presence of potential interactions, the use of several types of medications and the number of comorbidities. Treatment complexity was also a factor strongly associated with polypharmacy; for each point increase in the medication regimen complexity index (MRCI), the likelihood of polypharmacy increased 2.3-fold. Conclusions Polypharmacy is frequent among PLWH in Spain and contributes to a relevant extent to treatment complexity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect